Ocugen, Inc (2H51)

Currency in EUR
0.94
0.00(0.00%)
Closed·
2H51 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.920.99
52 wk Range
0.471.53
Key Statistics
Bid/Ask
0.93 / 0.96
Prev. Close
0.95
Open
0.98
Day's Range
0.92-0.99
52 wk Range
0.47-1.53
Volume
105.93K
Average Volume (3m)
180.98K
1-Year Change
-36.7%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2H51 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Ocugen, Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Ocugen, Inc Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Compare 2H51 to Peers and Sector

Metrics to compare
2H51
Peers
Sector
Relationship
P/E Ratio
0.0x−1.9x−0.5x
PEG Ratio
0.00−0.020.00
Price/Book
0.0x3.7x2.6x
Price / LTM Sales
0.0x80.3x3.2x
Upside (Analyst Target)
0.0%186.4%41.6%
Fair Value Upside
Unlock20.8%6.0%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

2H51 Income Statement

People Also Watch

2.540
OPEN
+4.96%
75.50
OKLO
+1.22%
7.390
BBAI
-5.26%
47.430
RKLB
-1.45%
18.870
QBTS
-4.50%

FAQ

What Stock Exchange Does Ocugen, Inc Trade On?

Ocugen, Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Ocugen, Inc?

The stock symbol for Ocugen, Inc is "2H51."

What Is the Ocugen, Inc Market Cap?

As of today, Ocugen, Inc market cap is 271.11M.

What Is Ocugen, Inc's Earnings Per Share (TTM)?

The Ocugen, Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 2H51 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Ocugen, Inc Stock Split?

Ocugen, Inc has split 0 times.

What is the current trading status of Ocugen, Inc (2H51)?

As of 28 Jul 2025, Ocugen, Inc (2H51) is trading at a price of 0.94, with a previous close of 0.95. The stock has fluctuated within a day range of 0.92 to 0.99, while its 52-week range spans from 0.47 to 1.53.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.